Pathway Health is one of the largest providers of out-of-hospital pain management services in . The Company owns and operates 9 community-based clinics across 4 provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches. Pathway Health's patient care programs utilize an interdisciplinary approach that is guided by trained pain specialists, physical and occupational therapists, psychologists, nurses, and other healthcare providers. Pathway Health has also developed an expertise in harm reduction where medicinal cannabis is being used as an alternative to traditional opioids.

1. page 1
Investor Presentation
October 2020

2. page 2
DISCLAIMER
Certain statements contained in this presentation constitute forward-looking statements. The words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions typically are
used to identify forward-looking statements. By their nature, forward-looking statements and information involve
known and unknown opportunities, costs, risks and uncertainties that may cause actual results to differ materially
from those anticipated. Except for statements of historical fact, certain information contained herein constitutes
forward-looking statements which include management’s assessment of future plans and operations and are based
on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect.
The use of forward-looking statements reflects our current views, expectations, estimates and/or projections with
respect to our performance, business and future events, and in this presentation includes statements relating to,
among others: expectations regarding our business; expectations relating to our business goals, objectives and
schedules; expectations regarding the cannabinoid based therapy industry, including Canada’s position therein;
expectations regarding the acceptance of cannabinoid based therapies in the medical community; expectations
regarding our clinical development plans; expectations regarding development of new intellectual property, including
from cannabinoid product combinations; expectations related to the anticipated closing of the subscription receipt
offering and reverse take-over with a Capital Pool Company; the terms and conditions of the subscription receipt
offering; and the use of proceeds from the subscription receipt offering. Forward-looking statements are prepared by
management and based on the then-current expectations, forecasts and assumptions about the business and the
industry and markets in which we operate, including, among others: that there will be no unforeseen delays,
disruptions, market forces, regulations or laws that will prevent us from operating our business; that we will be able
to obtain the capital we require; that the subscription receipt offering has closed; that the escrow release conditions
in respect of the subscription receipt offering have been fulfilled; and that the reverse take-over has been completed.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and
assumptions which are difficult to predict, including, without limitation: that we may experience unforeseen delays,
financing difficulties or costs that will impact our projects, operations, financial performance or liquidity; that we will
not be able to advance our business plan or continue operations; that we will not be able to obtain insurance for our
operations; that we will not be able to protect our intellectual property; that we will not be able to develop and
commercialize, or obtain regulatory approvals to commercialize, products derived from our intellectual property; that
we will not be able to recruit physicians for our clinics; that regulatory approvals of products developed from our
intellectual property may result in significant delays; that development of cannabinoid based therapies may expose
us to liability claims in excess of our insurance coverage; and those risks relating to the occurrence of national
disasters, hostilities, acts of war or terrorism, our reputation, our key personnel, competition, employee relations,
changes in the cannabinoid based therapy market generally, potential downturns in economic conditions, pandemics,
foreign exchange fluctuations, fluctuations in the currency markets, inflationary pressures, changes in interest rates,
changes in regulatory requirements which may alter or prohibit investment in our business, or changes in national
and local government legislation, taxation, controls, regulations and political or economic developments in Canada or
any other country in which we operate or intend to operate.
These risks, as well as others, could cause actual results and events to differ materially from those anticipated in
such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking
statements and information, which are qualified in their entirety by this cautionary statement. These statements
speak only as of the date of this presentation and we do not undertake any obligations to update such forward-
looking statements, except as required by applicable securities law.
To the extent any forward-looking information in this presentation constitutes “future-oriented financial
information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is
being provided to demonstrate the potential benefits of the company’s business plans and strategies, and the reader
is cautioned that this information may not be appropriate for any other purpose and the reader should not place
undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial
information and financial outlooks, as with forward-looking information generally, are, without limitation, based on
the assumptions and subject to the risks set out herein. The company’s results of operations and estimated and
forecasted revenue may differ materially from management’s current expectations. Such information is presented
for illustrative purposes only and may not be an indication of the company’s actual future results of operations or
earnings.
Market and industry data contained in this presentation is based upon information, surveys or studies conducted by
independent third parties and independent industry or general publications and management’s knowledge of, and
experience in, the markets in which we operate or intend to operate. We have no reason to believe that such third-
party information is false or misleading in any material respect, however market and industry data is subject to
variation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data,
the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical
survey. This third-party information has not been independently verified by us or any of our respective directors,
officers or representatives and no representation is given as to the accuracy of any of the data from third party
sources referred to in this presentation.
The securities being offered pursuant to the subscription receipt offering are being offered on a private placement
basis in reliance upon prospectus and registration exemptions under applicable securities legislation. Resale of the
securities offered hereunder will be subject to restrictions under applicable securities legislation, which will vary
depending on the relevant jurisdiction. Generally, such securities may be resold only pursuant to an exemption from
the prospectus and registration requirements of applicable securities legislation or pursuant to an exemption order
granted by appropriate securities regulatory authorities.
The securities being offered pursuant to the subscription receipt offering have not, nor will they be, registered under
the United States Securities Act of 1933, as amended, or the securities laws of any state of the United States and may
not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of
U.S. registration or an applicable exemption from the U.S. registration requirements. This presentation does not
constitutes an offer for sale of securities in the United States.

3. page 3
• One of the largest providers of chronic pain services in
Canada
• 3-year revenue growth - $600k (2018) to $12.6 million
(2020) 1
• Largest medical cannabis telehealth network in Canada
• Leading partner with Canadian pharmacy companies for
medical cannabis consultations
• Agreements signed covering >1,800 retail pharmacy
locations
• MySpark TM proprietary IT – ‘actionable digital intelligence’
1. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in
relation to the acquisition of NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.

4. page 4
Wayne Cockburn
President
Ken Yoon
CEO
Over 25 years of healthcare experience, including
20 years at the C-level, specializing in strategic
planning, corporate finance and capital market
strategies, corporate partnering, corporate
governance and mergers and acquisitions. Mr.
Cockburn brings over 35 years of capital market
experience and has served on the board of
directors of U.S. and Canadian private and public
companies for more than 20 years.
25 years of experience in consulting, financing,
investing and building innovative private and
public companies with over $500M in
transactions. Prior to PHC, Mr. Yoon was CFO at a
TSX listed pharmaceutical company and a private
nanotech company, an investment professional at
what was one of largest venture capital firms in
Canada, and held several positions at Ernst &
Young, notably as a co-founder of a multi-
disciplinary business advisory group. Mr. Yoon is a
CPA, CA, holds an MBA, Law Degree, and BSc.
Over 30 years of executive level leadership
experience in healthcare. Mr. Wei has a track
record for developing and delivering innovative
allopathic and complementary medicine models
in North America.
Mr. Wei is a co-founder of The Clinic Network
and has helped grow PHC to be a Canadian
delivery system with corporate and joint-venture
clinics, in multiple healthcare disciplines. Mr.
Wei has acted as a Director on multiple Canadian
and international company Boards.
Kim Wei
Chief Commercial Officer

5. page 5
Over 20 years of experience in various facets of
the healthcare sector. Mr. Sandhu is the former VP
of Medical Operations and Business Optimization
for National Access Cannabis Medical. Mr. Sandhu
is also an active clinical pharmacist, who has a
passion for developing innovative programs in
regulated environments. In 2014, he was a
recipient of the Trillium Health Partners Allied
Health Professional Award. Mr. Sandhu holds a
Professional Certificate in Cannabis Science and
Medicine from the University of Vermont’s Larner
College of Medicine.
Pram Sandhu
VP, Pharmacy Programs & Regulatory Affairs
Aura Balboa
CFO
Over 15 years of finance and operations
experience to PHC. Ms. Balboa began her career
in public accounting with Deloitte. She then held
a number of finance roles with increasing
responsibilities at multiple pharmaceutical
companies both in Canada and the US. Her most
recent role was Director of Finance at Acerus
Pharmaceuticals Corporation, a Canadian
pharmaceutical company listed on the TSX.

6. page 6
Mr. Steele is an engineer and financier
with over 30 years of experience in
structured investments and new business
start-ups. Mr. Steele has provided
consulting services to various industry
sectors including real estate, mining, oil
and gas, and the Canadian medical
cannabis sector. Since 2013 Mr. Steele has
consulted to or provided financing to
various companies in the Canadian
medical cannabis industry. Mr. Steele
graduated from the University of
Waterloo with a P.Eng (BASc) in civil
engineering and received his MBA in
1981.
Ms. Wright has over 20 years of
management experience in the
construction and property management
industries. Currently, Ms. Wright is the
President of Alwright Investments Inc., a
Canadian property management and
investment company she founded in
2012. Ms. Wright has served as a director
on several boards of private companies in
both Canada and the United States. Ms.
Wright graduated from the University of
Toronto in 1991 and holds a Bachelor of
Science.
Mr. Howling has over 25 years of
healthcare industry experience in senior
financial positions; including 11 years with
Bausch Health (formerly Biovail
Corporation), as CFO, and Senior VP,
Finance and Corporate Affairs; five years as
CFO of Acerus Pharmaceuticals
Corporation; and five years as CFO with
Pharma Patch PLC. During his career, Mr.
Howling has contributed to the success of
multiple start-up companies and has taken
multiple companies through the IPO
process. Mr. Howling is a graduate of the
ICD/Rotman Director Program and
formerly a Certified Public Accountant
(inactive license).
Michael Steele
Chairman
Alison Wright
Independent Director
Kenneth Howling
Independent Director
1. Ken Yoon (CEO) is also a member of the Board of Directors

7. page 7
PREVALENT
1 in 5 Canadian adults
experience chronic pain 1
LACK OF SPECIALISTS
Specialized pain services
are largely inaccessible
BURDENSOME
>$50 billion in health
care resources and
productivity losses 2
UNDER CAPACITY
1-3 Years average wait time for
treatment at publicly-funded
pain clinics in Canada 3
1 Schopflocher et al., 2011; Reitsma et al., 2011; Steingrimsdottir et al., 2017, Canadian Pain Task Force Report, June 2019
2 https://www.benefitscanada.com/benefits/health-benefits/chronic-pain-costs-employers-52439
3 http://www.canada.com/health/live+this+life+pain+Canadians+with+chronic+pain+struggling+find+help+hope/5485154/story.html

8. page 8
• Fragmented industry – opportunity for consolidator
• Accretive acquisitions - build on existing infrastructure
• Pharmacy partnerships
• Patient assessments for pain management/medical
cannabis; product branding and development
• Cannabis 3.0 (2021/22) – focus on medical, Cannabis
Health Products
• Partnering opportunities – Workers Comp, unions, insurance
companies, family medical practices, allied health, LPs, First
Nations, government, clinical trials
• Improve access for patients

9. page 9
• Network of pain clinics in
major markets across
Canada
• Interdisciplinary procedures
by trained pain specialists
• Largest medical cannabis
telehealth network in the
country
• Pharmacy partnerships
• MY SPARK TM
• Web-based platform
• Proprietary data
management system
• Referral portal for
doctors, allied health
clinicians, nurses,
pharmacists, patients
• Creating an online
community
• Slawner Ortho (Est. 1952)
• Leader in Montreal (and
surrounding areas) in
Orthotics, Prosthetics, and
Home Healthcare products
• Cannabis Health Products for
clinics and pharmacy
partners (in discussions)
• Co-branding opportunities

10. page 10
• Current 9 locations include Toronto, Montreal (3),
Chateauguay, Magog, Saskatoon, Winnipeg, Selkirk
• Goal of 12 – 15 clinics across Canada
• Established clinics targeted for BC, AB and East
Coast through acquisition or affiliation
• Expansion of interventional pain model into current
locations – ketamine infusions, image-guided
therapies, etc.
• Continued acquisition of new patients
• Accretive to existing active base of >50,000
patients

11. page 11
“The Cannabis Health Products (CHP) category is expected to
grow exponentially in the coming years. ”
• Cannabis 3.0 - bringing the benefits of cannabis derivatives (e.g. CBD) into mainstream health products
• NPA’s1 pitch to the CDN government – “(P)harmacists have an important role in providing clinical
information to patients at the point of sale.”
• Pharmacies have limited or no experience with the category - New consumer packaged goods category
Neighbourhood Pharmacy Association Position Statement 2021
1. Neighbourhood Pharmacy Association

12. page 12
• SIGNED AGREEMENTS
• PharmaChoice, Sobeys, Lovell, others - ~1,800 pharmacy locations and growing
• PHARMACIST EDUCATION & CERTIFICATION
• Canadian Council on Continuing Education in Pharmacy medical cannabis education for pharmacists (bilingual)
• Program owned by, and exclusive to PHC
• MEDICAL CANNABIS MANAGEMENT SYSTEM (MCMS)
• Pharmacies provide access points for medical cannabis care
• Pharmacists offer medical cannabis assessments to pharmacy patients
• Connected to Pathway Health for further evaluation
• PRODUCT DEVELOPMENT & DISTRIBUTION (in development)
• Co-branding opportunities
• Secure retail pharmacy shelf space for future CBD OTC product distribution

13. page 13
Pharmacy Connection August 30, 2018
1. https://chfa.ca/en/regulatory/CBD-Economic-Report
2. https://mjbizdaily.com/chart-week-profit-margins-infused-products-can-sky-high/
3. Canadian Pharmacists Association, https://www.pharmacists.ca/pharmacy-in-canada/pharmacists-in-canada/
• 2021 Canadian Health Food Association report
estimates CBD market in Canada at $1.9 billion1
• Forecast legal changes to market worth $2.45
billion by 20231
• Profit margins can be significantly higher than the
average for other consumer goods such as alcohol,
beer, wine, soft drinks and cigarettes2
• Canada has approximately 42,500 licensed pharmacists
working in more than 10,000 pharmacies3

14. PLPs 1
page 14
Physicians
Pharmacies
MY
1. Preferred Licensed Producers
Patient
Portal

15. page 15
• Regional market expansion
• Continue rollup of patients and select clinics
• Expand new clinical services to existing clinics
• Sign additional pharmacy agreements for new patients
• New pharmacy agreements on Cannabis Health
Products – development, distribution and co-branding

16. page 16
LP Revenue Provincial Billing Non-Insured Billing Product Sales
31.4%
46.8%
17.8%
4%
2018
Revenue (C$MM) 2
$12.6
$6.6
$0.6
2020E
2019
$3.9
• Education and
marketing revenue
• 100% gross margins
$5.9
• Physician billings
• 20% gross margins1
$0.5
• Patient private pay
• 80% gross margins
$2.2
• Quebec orthopaedic sales
• 70% gross margins
1. Gross margins on Provincial Billings expected to increase as further integration of recent acquisitions occurs.
2. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition
of NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.

17. page 17
Akumin Inc.
Carebook Technologies Inc.
CloudMD Software and Services Inc.
Empower Clinics
Greenbrook TMS Inc.
Jack Nathan Health
MCI OneHealth
Medical Facilities Corp.
MindBeacon Holdings Inc.
Neupath Health Inc.
Skylight Health
ThinkResearch (TRC Holdings)
VitalHub Corp
WELL Health Technologies
1. High and low removed. Stock prices dated July 21, 2021
2. Based on reported 2020 financials
-
2.0
4.0
6.0
8.0
10.0
12.0
TEV/REV CAP/REV
Mean Median PHC.V

18. page 18
Percentage Shares
Investor Group Ownership Outstanding
Cura-Can Health Corp. 55.5% 51,638,711
Convertible notes 11.6% 10,864,108
CPC (Colson Capital) 3.1% 2,856,171
Canaccord sub receipts 29.6% 27,600,000
Shares to Agents 0.2% 150,000
GRAND TOTAL 100% 93,108,990
113,497,218 fully diluted shares outstanding. No derivative securities
have an exercise price less than issue price of $0.50 per share

19. page 19
• >10,000 patient visits in 2020
• TCN completed 5 acquisitions since January 2019 to become the nation’s largest
chronic pain telemedicine network. Growing database of more than 350,000
patients for product distribution and data analytics.
Largest out-of-
hospital chronic
pain clinic in
Canada
Proven execution
and strategic
growth
• Revenue has grown from $600K to almost $13 million in 3 years. 1
• Signed 6 agreements in 2020 with some of the nation’s largest retail pharmacies
 becoming the leading referral partner for pain products and services for
thousands of Canadian pharmacies.
• Developing a unique IT platform allowing the company to scale pharmacy
initiative and expand its telemedicine services to many physicians.
• Expertise and experience to grow the business to become the dominant out-of-
hospital pain management business in Canada.
Proven
management
1. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to
the acquisition of NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.

20. page 20
Wayne Cockburn,
President
(905) 505-0770
wayne.cockburn@pathwayhealth.ca
Investor Relations
Dave Burwell,
Vice President, The Howard Group
(403) 410-7907
dave@howardgroupinc.com